Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ: LEXX )

2.290 -0.080 (-3.38%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of Antiviral Drug Studies, Strategy Moving Forward
Via CannabisNewsWire
Topics Animal Testing
Exposures Animal Testing
Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
All objectives evaluating DehydraTECH™ drug delivery platform successfully achieved KELOWNA, BC / ACCESSWIRE / July 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Death Intellectual Property
Exposures Animal Testing COVID-19 Death
21 Stocks Moving in Thursday's Pre-Market Session
Gainers PainReform Ltd (NASDAQ: PRFX) shares rose 123% to $7.00 in pre-market trading. Second Sight Medical Products Inc (NASDAQ: EYES) shares rose 29% to $5.57 in pre-market... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares surged 159.2% to close at $5.34 on Wednesday after the company received a $28.3 million purchase order from Brazil's... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Second Sight Medical (NASDAQ:EYES 
Via Benzinga
Mid-Afternoon Market Update: Dow Jumps 250 Points; Sleep Number Shares Slide After Q2 Results
Toward the end of trading Wednesday, the Dow traded up 0.73% to 34,765.42 while the NASDAQ rose 0.66% to 14,594.38. The S&P also rose, gaining 0.69% to 4,352.90. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Chembio Diagnostics (NASDAQ:CEMI) stock rose 189.72% to $5.97 during Wednesday's regular session. Trading volume for Chembio Diagnostics's stock is 265.3... 
Via Benzinga
Mid-Day Market Update: Crude Oil Up 4%; Chembio Diagnostics Shares Spike Higher
Midway through trading Wednesday, the Dow traded up 0.79% to 34,785.02 while the NASDAQ rose 0.59% to 14,584.15. The S&P also rose, gaining 0.70% to 4,353.50. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares jumped 218.7% to $6.57 after the company received a $28.3 million purchase order from Brazil's Bio-Manguinhos to... 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Significantly Enhanced Delivery of Colchicine
Via CannabisNewsWire
Mid-Morning Market Update: Markets Open Higher; Coca-Cola Tops Q2 Views
Following the market opening Wednesday, the Dow traded up 0.62% to 34,727.53 while the NASDAQ rose 0.40% to 14,557.04. The S&P also rose, gaining 0.52% to 4,345.65. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Chembio Diagnostics (NASDAQ: CEMI) shares rose 102.91% to $4.18 during Wednesday's pre-market session. The market value of their outstanding shares is at $84.6 million.... 
Via Benzinga
Lexaria Stock Is Trading Higher As DehydraTECH Delivered Colchicine Can Potentially Treat COVID-19, Side Effects From mRNA Shots
Lexaria Bioscience Corp (NASDAQ: LEXX) has announced that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. The study... 
Via Benzinga
Exposures COVID-19
Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects KELOWNA, BC / ACCESSWIRE / July 21, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Intellectual Property
Exposures Animal Testing COVID-19 Intellectual Property
CannabisNewsBreaks – Why Lexaria Bioscience Corp. (NASDAQ: LEXX) Is ‘One to Watch’
Via CannabisNewsWire
New Patent Expands Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Suite to 20 Granted Worldwide (First in Japan)
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Shares Are Trading Higher On Completion Of Antiviral Drug Molecular Characterization Study
Lexaria Bioscience Corp (NASDAQ: LEXX) has announced results from its antiviral drug molecular characterization study VIRAL-MC21-1, completed by Canada's... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Alterity Therapeutics (NASDAQ:ATHE) shares rose 13.66% to $1.58 during Thursday's pre-market session. The market value of their outstanding shares is at $63.3... 
Via Benzinga
Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council
VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs KELOWNA, BC / ACCESSWIRE / July 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"),... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Considerable IP Portfolio with Patent Protection in Japan
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Receives Patent Protection in Japan
New patent granted in Japan adds to existing patents in the EU, the U.S., India and Australia KELOWNA, BC / ACCESSWIRE / July 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Delists from CSE to Focus Efforts on Most Effective Drug Platform Outcomes
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive Results From its Recent Animal Study on the Effectiveness of its DehydraTECH Drug Delivery Technology
Via CannabisNewsWire
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets
KELOWNA, BC / ACCESSWIRE / July 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that on... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Announces 2021 Annual Meeting Results
KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19 Product Safety
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
New York, New York--(Newsfile Corp. - June 17, 2021) - PCG Digital -- Lexaria Bioscience Corp. (NASDAQ: LEXX) hit a... 
Via Newsfile
Exposures COVID-19 Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Clearside Biomedical (NASDAQ:CLSD) stock increased by 50.99% to $4.56 during Tuesday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 KELOWNA, BC / ACCESSWIRE / June 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Lexaria Provides Progress Report on Six R&D Programs
- All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine - These studies are part of Lexaria's 2021 applied... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Animal Testing Intellectual Property
Exposures Animal Testing COVID-19 Intellectual Property
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.